Altimmune reported statistically significant Phase 2 results for pemvidutide (pemvi) in alcohol use disorder, showing a reduction in heavy drinking days versus placebo. The company positioned the effect as robust across secondary endpoints, including World Health Organization Risk Drinking Levels and zero heavy drinking days. Separately, Altimmune also highlighted strategic planning toward Phase 3 after the Phase 2 topline, framing the results as among the strongest it has seen for AUD. The dual GLP-1 and glucagon receptor mechanism is designed to leverage metabolic and neurobehavioral pathways relevant to addictive behaviors. Together, the update keeps Altimmune’s AUD program on a path toward pivotal evaluation while potentially reinforcing its broader metabolic disease development strategy.